Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NIRAMAI has developed and commercialized an AI-powered thermal imaging solution ("Thermalytix") for early-stage breast cancer detection. Their technology has demonstrated high sensitivity and specificity—non-inferior or superior to mammography in certain populations—and works across all ages and breast densities. The company’s SMILE‑100 system received US FDA clearance as an adjunctive diagnostic tool. Over three clinical trials have been published with positive results, including higher accuracy than mammography in some settings.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NIRAMAI Health Analytix.